Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 842 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $80,991.98. Following the sale, the senior vice president directly owned 3,700 shares in the company, valued at $355,903. This trade represents a 18.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $86,423.58.

Mirum Pharmaceuticals Stock Up 2.4%

Mirum Pharmaceuticals stock traded up $2.35 during mid-day trading on Tuesday, hitting $99.27. The company’s stock had a trading volume of 679,931 shares, compared to its average volume of 877,176. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $99.44. The firm’s 50 day moving average is $77.82 and its 200 day moving average is $71.21. The company has a market cap of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue was up 47.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) EPS. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MIRM shares. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Citizens Jmp increased their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Evercore ISI reissued an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Finally, Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $104.92.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
• Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long‑range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
• Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
• Positive Sentiment: Momentum / new 52‑week high after upgrades — The stock hit a fresh 52‑week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52‑Week High
• Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short‑term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MIRM. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Mirum Pharmaceuticals by 22.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,815 shares of the company’s stock worth $1,170,000 after buying an additional 2,700 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Mirum Pharmaceuticals by 377.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,274 shares of the company’s stock valued at $733,000 after buying an additional 7,332 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $240,000. Wetzel Investment Advisors Inc. bought a new position in Mirum Pharmaceuticals during the fourth quarter worth $205,000. Finally, Palumbo Wealth Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 19.8% during the 4th quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock worth $401,000 after buying an additional 840 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.